Sana Biotechnology Change in Accounts Receivable 2020-2025 | SANA

Sana Biotechnology change in accounts receivable from 2020 to 2025. Change in accounts receivable can be defined as the increase or decrease in accounts receivable for the given period.

Sana Biotechnology Change in Accounts Receivable 2020-2025 | SANA

Sana Biotechnology change in accounts receivable from 2020 to 2025. Change in accounts receivable can be defined as the increase or decrease in accounts receivable for the given period.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$249.7B
Amgen (AMGN)$159.6B
Gilead Sciences (GILD)$147.3B
Vertex Pharmaceuticals (VRTX)$101.1B
Bristol Myers Squibb (BMY)$98.2B
GSK (GSK)$81.6B
CSL (CSLLY)$68.5B
Regeneron Pharmaceuticals (REGN)$62.6B
Alnylam Pharmaceuticals (ALNY)$60.1B
Argenex SE (ARGX)$40.5B
Insmed (INSM)$27.4B
BioNTech SE (BNTX)$26.8B
Royalty Pharma (RPRX)$21.5B
Biogen (BIIB)$20.4B
Incyte (INCY)$16.8B
Genmab (GNMSF)$15.9B
Illumina (ILMN)$15.5B
Genmab (GMAB)$15.4B
Ascendis Pharma (ASND)$11.8B
BioMarin Pharmaceutical (BMRN)$11.1B
QIAGEN (QGEN)$10.9B
Moderna (MRNA)$10.5B
Swedish Orphan Biovitrum (BIOVF)$10.3B
Exelixis (EXEL)$10.2B
Verona Pharma American Depositary Share (VRNA)$9B
Exact Sciences (EXAS)$8.9B
Bio-Techne Corp (TECH)$8.5B
Blueprint Medicines (BPMC)$8.3B
Halozyme Therapeutics (HALO)$8.3B
Roivant Sciences (ROIV)$8B